secwatch.observer — SEC 8-K summary
======================================

Issuer:     Dianthus Therapeutics, Inc. /DE/ (DNTH)
CIK:        0001690585
Form:       8-K
Filed at:   2026-05-05T23:59:59+00:00
Accession:  0001690585-26-000021
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Dianthus Q1 net loss $40.8M; cash $1.2B; claseprubart and DNTH212 advance
-------------------------------------------------------------------------

- Net loss $40.8M ($0.85/share) vs $29.5M ($0.82) in Q1 2025; R&D spend $34.5M up from $27.0M.
- Cash $1.2B at March 31, including $719M gross from March public offering; runway into 2030.
- Claseprubart: Early GO in CAPTIVATE CIDP trial; Phase 3 gMG trial mid-2026 with top-line 2H'28.
- DNTH212: Priority indications SjD, SLE, DM; Phase 1 healthy volunteer data expected 2H'26.
- Orphan Drug Designation for claseprubart in MG; FDA agreed to remove ANA screening and DIL reclassification.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/0001690585-26-000021-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1690585/000169058526000021/dnth-20260505.htm
  HTML page:      https://secwatch.observer/filing/0001690585-26-000021

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer